<p>Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - 獲取免費報告) 的股價在週五交易中上漲了 2.7%。該公司的股價最高達到 $6.59，最後交易價為 $6.58。在交易中，共成交 3,679 股，較平均交易量 45,397 股下降了 92%。該股票此前收盤價為 $6.41。</p>
<p>獲取 <strong>Armata Pharmaceuticals</strong> 的提醒：</p>
<h2>Armata Pharmaceuticals 股票表現</h2>
<p>該公司的市值為 2.3958 億美元，市盈率為 -4.06，貝塔係數為 1.24。該股票的 50 日移動平均價格為 $6.07，200 日移動平均價格為 $3.78。</p>
<h2>Armata Pharmaceuticals 的機構交易</h2>
<p>一家機構投資者最近在 Armata Pharmaceuticals 股票中建立了新頭寸。GSB Wealth Management LLC 在第二季度購買了 Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - 免費報告) 的新股份，根據其最近向 SEC 的披露，該基金購買了 30,000 股公司股票，價值約為 $57,000。GSB Wealth Management LLC 在其最近向 SEC 的備案中擁有 Armata Pharmaceuticals 的 0.08%。目前，3.57% 的股票由機構投資者和對沖基金持有。</p>
<h2>Armata Pharmaceuticals 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Armata Pharmaceuticals, Inc 是一家臨牀階段的生物技術公司，開發針對抗生素耐藥細菌感染的靶向噬菌體療法。該公司的專有平台利用自然發生的病毒，選擇性地感染並摧毀細菌病原體，提供了一種應對在醫院和社區環境中造成重大挑戰的耐藥菌株的新方法。</p>
<p>Armata 的產品管線包括針對銅綠假單胞菌的噬菌體候選藥物，這是一種常見的醫院獲得性肺炎和囊性纖維化患者感染的病因，以及金黃色葡萄球菌和其他優先病原體。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更喜歡的五隻股票比 Armata Pharmaceuticals 更好</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者提醒：微型 “$3 人工智能奇蹟股票” 即將爆發</li>
<li>是否可以從資本利得税中扣除任何費用？</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 在 Armata Pharmaceuticals 嗎？</h2>
<p>在考慮 Armata Pharmaceuticals 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Armata Pharmaceuticals 並不在名單上。</p>
<p>雖然 Armata Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ARMP

<p>Armata Pharmaceuticals (NYSEAMERICAN:ARMP) 的股價上漲了 2.7%，達到了 6.58 美元，儘管交易量下降了 92%。該公司的市值為 2.3958 億美元，市盈率為-4.06。機構投資者持有該股票的 3.57%。分析師給予買入評級，但建議其他股票可能是更好的投資選擇</p>

<p>Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report)'s stock price shot up 2.7% during trading on Friday . The company traded as high as $6.59 and last traded at $6.58. 3,679 shares traded hands during trading, a decline of 92% from the average session volume of 45,397 shares. The stock had previously closed at $6.41.</p>
<div class="lb-trans"><p>Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - 獲取免費報告) 的股價在週五交易中上漲了 2.7%。該公司的股價最高達到 $6.59，最後交易價為 $6.58。在交易中，共成交 3,679 股，較平均交易量 45,397 股下降了 92%。該股票此前收盤價為 $6.41。</p>
</div><p>Get <strong>Armata Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Armata Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Armata Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Armata Pharmaceuticals 股票表現</h2>
</div><p>The firm has a market capitalization of $239.58 million, a P/E ratio of -4.06 and a beta of 1.24. The stock has a fifty day moving average price of $6.07 and a two-hundred day moving average price of $3.78.</p>
<div class="lb-trans"><p>該公司的市值為 2.3958 億美元，市盈率為 -4.06，貝塔係數為 1.24。該股票的 50 日移動平均價格為 $6.07，200 日移動平均價格為 $3.78。</p>
</div><h2>Institutional Trading of Armata Pharmaceuticals</h2>
<div class="lb-trans"><h2>Armata Pharmaceuticals 的機構交易</h2>
</div><p>An institutional investor recently bought a new position in Armata Pharmaceuticals stock. GSB Wealth Management LLC purchased a new stake in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 30,000 shares of the company's stock, valued at approximately $57,000. GSB Wealth Management LLC owned 0.08% of Armata Pharmaceuticals as of its most recent filing with the SEC. 3.57% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家機構投資者最近在 Armata Pharmaceuticals 股票中建立了新頭寸。GSB Wealth Management LLC 在第二季度購買了 Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - 免費報告) 的新股份，根據其最近向 SEC 的披露，該基金購買了 30,000 股公司股票，價值約為 $57,000。GSB Wealth Management LLC 在其最近向 SEC 的備案中擁有 Armata Pharmaceuticals 的 0.08%。目前，3.57% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Armata Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Armata Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company's proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.</p>
<div class="lb-trans"><p>Armata Pharmaceuticals, Inc 是一家臨牀階段的生物技術公司，開發針對抗生素耐藥細菌感染的靶向噬菌體療法。該公司的專有平台利用自然發生的病毒，選擇性地感染並摧毀細菌病原體，提供了一種應對在醫院和社區環境中造成重大挑戰的耐藥菌株的新方法。</p>
</div><p>Armata's pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.</p>
<div class="lb-trans"><p>Armata 的產品管線包括針對銅綠假單胞菌的噬菌體候選藥物，這是一種常見的醫院獲得性肺炎和囊性纖維化患者感染的病因，以及金黃色葡萄球菌和其他優先病原體。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Armata Pharmaceuticals</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票比 Armata Pharmaceuticals 更好</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者提醒：微型 “$3 人工智能奇蹟股票” 即將爆發</li>
<li>是否可以從資本利得税中扣除任何費用？</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Armata Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Armata Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Armata Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Armata Pharmaceuticals 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Armata Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Armata Pharmaceuticals 並不在名單上。</p>
</div><p>While Armata Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Armata Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Armata Pharmaceuticals（NYSEAMERICAN:ARMP）股價上漲 2.7% - 現在仍然值得購買嗎？